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Persistent infection with oncogenic types of human papillomavirus (HPV) is the most important risk 
factor associated with cervical cancer.  This study detected the oncogenic HPV genotypes in cervical 
neoplasia in relation to clinicopathological ﬁndings using a cross-sectional descriptive method in 2011 
and 2012.  Cervical swabs and colposcopy-directed cervical biopsy tissues were collected from 108 
women (median age 45 years; range 20-78) showing cervical cytological changes at Sanpya General 
Hospital,  Yangon,  Myanmar.  HPV DNA testing and genotyping were performed by polymerase chain 
reaction and restriction fragment length polymorphism.  HPV was identiﬁed in women with cervical 
intraepithelial neoplasia (CIN) 1 (44.4ｵ),  CIN2 (63.2ｵ),  CIN3 (70.6ｵ),  and squamous cell carcinoma 
(SCC) (74.1ｵ).  The association between cervical neoplasia and HPV positivity was highly signiﬁcant 
(p＝0.008).  Most patients infected with HPV were between 40-49 years of age,  and the youngest were 
in the 20- to 29-year-old age group.  The most common genotype was HPV 16 (65.6ｵ) with the follow-
ing distribution: 70ｵ in CIN1,  41.7ｵ in CIN2,  91.7ｵ in CIN3,  and 60ｵ in SCC.  HPV-31 was the sec-
ond-most frequent (21.9ｵ): 30ｵ in CIN1,  33.3ｵ in CIN2,  8.3ｵ in CIN3,  and 15ｵ in SCC.  The third-
most frequent-genotype was HPV-18 (7.8ｵ): 8.3ｵ in CIN1,  and 20ｵ in SCC.  Another genotype was 
HPV-58 (4.7ｵ): 16.7ｵ in CIN1 and 5ｵ in SCC.  The majority of CIN/SCC cases were associated with 
HPV genotypes 16,  31,  18,  and 58.  If oncogenic HPV genotypes are positive,  the possibility of cervi-
cal neoplasia can be predicted.  Knowledge of the HPV genotypes distribution can predict the eﬀective-
ness of the currently used HPV vaccine.
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uman papillomavirus (HPV) infection is the most 
common sexually transmitted disease worldwide 
[1],  with the prevalence of high-risk (HR)-HPV in 
asymptomatic women varying from 2ｵ to 44ｵ [2].  
Most HPV infections are transient: 54ｵ resolve 
spontaneously in one year [3] and 91ｵ in two years 
[4].  However,  10ｵ to 60ｵ of women positive for 
HPV will have the same genotype one year later [1].
　 Worldwide,  cervical cancer is the third-most com-
mon cancer in women and accounts for 9ｵ of all 
H
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female cancers [5].  In Myanmar,  the estimated cervi-
cal cancer incidence was 26.4ｵ in 2008 [6].  Cervical 
cancer ranks as the second-most frequent cancer 
among women in Myanmar.  Data are not yet available 
on the HPV burden in the general population of 
Myanmar.  However,  in South-eastern Asia,  about 
8.4ｵ of women in the general population are esti-
mated to harbor cervical HPV infection and 72.6ｵ of 
invasive cervical cancers (ISCCs) are attributed to 
HPV 16 or 18 [7].
　 The risk of mild cervical changes leading to severe 
cervical changes,  i.e.,  cervical intraepithelial neopla-
sia 3 (CIN3),  is higher when HR-HPV types,  espe-
cially HPV genotype 16,  are detected [8].  The pos-
sibility for the regression of CIN2 cervical changes 
caused by HPV genotype 16 is lower than that for 
cervical changes caused by other HR-HPV types [9].  
Cervical intraepithelial changes regress when infection 
with HR-HPV resolves spontaneously [10].
　 HR-HPV-positive women even without cytological 
changes have a 210-fold higher risk of developing 
CIN3 in 6 years as compared with HR-HPV-negative 
women [11].  Only 9 women per 10,000 will have CIN3 
if they are HR-HPV-negative with normal cytological 
ﬁndings [12].  HPV-16 is more likely to persist and 
is more aggressive compared with other types [13].  
Although the prevalence of HR-HPV has changed 
recently,  HPV genotypes 16 and 18 remain the most 
prevalent all over the world.  HPV types -31,  -33,  
and -45 compete to be the third-most prevalent in most 
countries,  though an increasing prevalence of HPV 
type 58 has been observed recently (mostly in East 
Asia).  However,  HPV types -16,  -18,  and -45 are 
the only types that are more common in their invasive 
forms than as precancerous lesions [14].
　 HPV typing has important prognostic and thera-
peutic value.  Information on the HPV type distribu-
tion in CIN and ISCC is crucial to predicting the 
future impact of HPV16/18 vaccines and screening 
programs and to establish appropriate post-vaccinal 
virologic surveillance.  The aim of this study was to 
determine the prevalence of HPV infection and of 
oncogenic HPV genotypes-16,  -18,  -31,  -33,  -35,  
-52,  and -58 in women with cervical neoplasia in rela-
tion to clinicopathological ﬁndings.
Materials and Methods
　 A cross-sectional descriptive study was carried out 
in women with cervical neoplasia in relation to clinico-
pathological ﬁndings in 2011 and 2012.  After informed 
consent was obtained,  cervical swabs and colposcopy-
directed cervical biopsy tissues were collected from a 
total of 108 women (median age 45 years; range 
20-78) with cervical neoplasia (CIN1,  CIN2,  CIN3 or 
squamous cell cancer) who received HPV DNA testing 
and genotyping at Sanpya General Hospital,  
Thingangyun,  Yangon.  Cervical cells and biopsy tis-
sues were collected in phosphate buﬀered saline and 
stored at －20℃.
　 DNA extraction. For DNA extraction,  the 
samples were suspended in 300µL of proteinase K and 
incubated at 50℃ for 2h and then treated with 
100µL of 5M sodium chloride (NaCl).  After centrifu-
gation,  the supernatant was treated with 900µL of 
ethanol.  DNA precipitates were collected by centrifu-
gation at 12,000rpm for 10min and washed with 
400µL of 70ｵ ethanol.  DNA was dissolved in 100µL 
of Tris with ethylene-diamine-tetra-acetic acid (TE).
　 HR-HPV testing. HPV-DNA testing was per-
formed using the polymerase chain reaction (PCR) 
method.  Consensus sequence primer pairs within the 
E6 and E7 open reading frames,  i.e.,  forward primer 
(pU-1M): 5ʼ-TGTCAAAAACCGTTGTGTCC-3ʼ and 
reverse primer (pU-2R): 5ʼ-GAGCTGTCGCTTAA 
TTGCTC-3ʼ) (oligo@sigma genosys-PCR, Japan),  
were used to amplify HR-HPV (HPV-16,  -18,  -31,  
-33,  -35,  -52b,  -58) [8].  The reaction mixture 
contained 0.15µL of taq polymerase (Applied Biosystems,  
Roche,  CA,  USA),  2µL 10Xbuﬀer,  3.2µL dNTPs,  
0.4µL of forward and reverse primers,  12.85µL dis-
tilled water and 1µL DNA.  The samples were sub-
jected to 35 cycles of ampliﬁcation using an ASTEC 
thermal cycler (ASTEC Co.  Ltd,  Fukuoka,  Japan).  
Each cycle included denaturation,  annealing and 
extension steps.  Detection of the PCR products was 
performed by electrophoresis on 6ｵ polyacrylamide 
gel (PAGE) at 200V for 30 min and by silver stain-
ing.
　 HPV genotyping. In PCR-positive cases,  HPV 
genotyping was analyzed by the restriction fragment 
length polymorphism method.  HPV genotypes were 
determined by PAGE and silver staining of the digest 
of the PCR products with the restriction enzymes,  
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Ava II (HPV-16,  HPV-18 and HPV-33),  Rsa I 
(HPV-31),  Bgl II (HPV-52b),  Acc I (HPV-58) and 
Ava I (HPV-35) (Wako,  Osaka,  Japan).  Enzymatic 
digestion was performed under the conditions recom-
mended by the manufacturer [8].
　 Statistical analysis. Data analysis was done by 
using Microsoft Oﬃce Excel 2007 and the Statistical 
Package for Social Sciences (SPSS-16),  i.e.,  the 
SPSS full version free download (http://en.softonic. 
com/s/spss-16-full-version-free-download/) accessed 
December,  2013.
Results
　 Among 108 women tested for HR-HPV,  64 (59.3ｵ) 
were positive as revealed by PCR bands around 
240bp～260bp (Fig.  1).  Analysis of the women posi-
tive for HR-HPV is shown in Table 1.  The association 
between cervical neoplasia and HR-HPV positivity was 
highly signiﬁcant (p＝0.008).  HPV genotyping was 
analyzed by the restriction fragment length polymor-
phism method.  Restriction analysis using AvaII revealed 
42 samples having 2 fragment bands at 155bp and 
80bp were of the HPV-16 genotype,  and 5 samples 
having 2 fragment bands at 170bp and 90bp were 
HPV-18.  Analysis using RsaI of 14 samples that had 
a broad band overlapping the 2 fragments at 119bp 
and 114bp showed them to be HPV-31.  Analysis 
using AccI of 3 samples that had a broad overlapping 
band in the 126bp and 118bp regions showed them to 
be HPV-58.  The most common genotype was HPV 
genotype 16 (65.6ｵ).  In this study,  HPV genotypes 
-33,  -35 and -52 were not detected.  The majority of 
CIN/squamous cell carcinoma (SCC) cases were 
associated with HPV genotypes -16,  -31,  -18,  and 
-58 (Table 2).
　 The proportions of HR-HPV in cervical neoplasia 
by age groups are shown in Table 3.  In this study,  
26.6ｵ of the women having cervical neoplasia 
infected with HR-HPV were in the 30- to 39-year age 
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Table 1　 Proportion of high-risk human papillomavirus infection in cervical neoplasia
HPV PCR
Histopathology
Total
CIN I CIN II CIN III/CIS SCC
Positive 20
(44.4%)
12
(63.2%)
12
(70.6%)
20
(74.1%)
64
(59.3%)
Negative 25
(55.6%)
7
(36.8%)
5
(29.4%)
7
(25.9%)
44
(40.7%)
Total (count)
(% within histopathology)
45
(100.0%)
19
(100.0%)
17
(100.0%)
27
(100.0%)
108
(100.0%)
603bp
310bp
281-271bp
234bp
194bp
1 2 3 6 11 12 13 M 14 15 16 17 18 19 20M 4 5 10987
Fig. 1　 Ampliﬁcation of HPV using pU1M/pU2R primers showing lane M,  molecular marker: ФX174/HaeIII digest; lane 1 - positive 
control,  lane 11 - negative control,  lanes 2,  3,  5,  6,  8,  9,  13,  14 to 20 - positive HPV DNA,  lanes 4,  7,  10,  12- negative HPV DNA,  
6% PAGE,  200V,  30min with silver staining.
group,  25ｵ were aged 40-49 years,  and 29.7ｵ were 
aged 50-59 years.  The youngest woman infected with 
HR-HPV was 20 years old,  and the oldest was 78 years 
old in this study.  Of the cases of HPV-16,  31ｵ were 
among women aged 30-39 years,  31ｵ were among 
50- to 59-year-old women,  and 28.6ｵ were among 
40- to 49-year-old women (Fig.  2Ａ).  A large per-
centage of HPV-18 cases (40ｵ) were in women aged 
＝/＞ 70 years and the same percentage (20ｵ) was 
found among women aged 20-29 years,  40-49 years,  
and 50-59 years (Fig.  2Ｂ).  As for HPV-31,  28.6ｵ 
of all cases were found in women aged 30-39 years,  
and the same percentage was found among women aged 
50-59 years (Fig.  2Ｃ).  HPV-58 was detected in 
women aged 60-69 years (66.7ｵ of HPV-58 cases) 
and women aged 50-59 years (33.3ｵ of HPV-58 
cases) (Fig.  2Ｄ).  Therefore,  HPV-16 was detected 
in 90.6ｵ of women with HPV positive cervical neo-
plasia aged between 30 to 59 years.  HPV-31 was 
detected in 78.6ｵ of women with HPV positive cervi-
cal neoplasia aged between 30 to 59 years.  HPV-18 
and HPV-58 were more commonly found in older aged 
group as 40ｵ of HPV-18 cases and 66.7ｵ of HPV 
-58 cases were found in women aged 60 years and 
above.  There was no signiﬁcant diﬀerence in the 
prevalence of HPV according to the clinical stage of 
cervical cancer (X2＝0.78,  p＝0.37).
Discussion
　 Data on the geographical distribution of HPV types 
in high-grade squamous intraepithelial lesion (HSIL) 
and ISCC are crucial for estimating the impact of 
HPV vaccines on cervical cancer and cervical screen-
ing programs.  A meta-analysis of the HPV distribu-
tion in Asia reported a mean prevalence of 14ｵ in 
women with normal cytology (NC) results and little 
variation between regions in Asia [16].  In South-
eastern Asia,  about 8.4ｵ of women in the general 
population are estimated to harbor cervical HPV 
infection,  and 72.6ｵ of ISCC,  33.3ｵ of HSIL,  and 
14.2ｵ of low-grade squamous intraepithelial lesion 
(LSIL) cases are attributed to HPV-16 or -18 [7].
　 The prevalence and distribution of HPV genotypes 
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Table 2　 Proportion of high-risk human papillomavirus genotypes in cervical neoplasia
HPV genotypes
Histopathology
Total
CIN I CIN II CIN III/CIS SCC
HPV-16 14
(70.0%)
5
(41.7%)
11
(91.7%)
12
(60.0%)
42
(65.6%)
HPV-18 0
(.0%)
1
(8.3%)
0
(.0%)
4
(20.0%)
5
(7.8%)
HPV-31 6
(30.0%)
4
(33.3%)
1
(8.3%)
3
(15.0%)
14
(21.9%)
HPV-58 0
(.0%)
2
(16.7%)
0
(.0%)
1
(5.0%)
3
(4.7%)
Total (count)
(% within histopathology)
20
(100.0%)
12
(100.0%)
12
(100.0%)
20
(100.0%)
64
(100.0%)
Table 3　 Proportion of high-risk human papillomavirus in cervical neoplasia by age groups
HPV PCR
Age Group (Years)
Total
20-29 30-39 40-49 50-59 60-69 ＝/＞70
Positive 4
(6.2%)
17
(26.6%)
16
(25.0%)
19
(29.7%)
4
(6.2%)
4
(6.2%)
64
(100.0%)
Negative 3
(6.8%)
10
(22.7%)
21
(47.7%)
9
(20.5%)
1
(2.3%)
0
(0%)
44
(100.0%)
Total (count)
(% within HPV PCR)
7
(6.5%)
27
(25.0%)
37
(34.3%)
28
(25.9%)
5
(4.6%)
4
(3.7%)
108
(100.0%)
varies greatly worldwide,  and these diﬀerences might 
be related to the complex geographical and biological 
interplay between diﬀerent HPV types and host immu-
nogenetic factors [17].  With the exception of Eastern 
Africa,  China,  Japan and Taiwan [18-19],  HPV-16 
is the most prevalent type in all parts of the world.  A 
meta-analysis done in 2011 found that 46.5ｵ of HSIL 
cases harbored HPV-16 and 8.9ｵ harbored HPV-18 
and in ISCC,  53.2ｵ of cases harbored HPV-16 and 
13.2ｵ harbored HPV-18.  The next 5 most common 
types in decreasing frequency were HPV-31,  -58,  
-33,  -45,  and -52 [20].
　 Martin et al.  [21] reported that 96.3ｵ of HSIL 
cases were positive for HPV,  and the most frequent 
type was HPV-16 (51ｵ),  followed by -52 (14ｵ) and 
-31 (11ｵ).  Jariene et al.  [22] revealed that 59ｵ of 
women with cervical neoplasia were positive for 
HR-HPV,  and 61.1ｵ of CIN1/CIN 1-2 cases and 
74.2ｵ of CIN2/CIN2-3/CIN3/carcinoma in situ cases 
were positive for HPV types-16,  -18 or -45.  In 
Myanmar,  Mu Mu Shwe et al.  [23] reported that 
49ｵ of women with abnormal cervical cytology and 
5ｵ with NC were positive for HR-HPV.  They were 
identiﬁed in 35.5ｵ of inﬂammatory smear cases,  60ｵ 
of atypical squamous cells of undetermined signiﬁ-
cance (ASCUS),  86.7ｵ of LSIL,  50ｵ of HSIL and 
100ｵ of SCC.  The detection of HPV genotypes 
showed the following: 60.4ｵ of HPV positive cases 
were HPV-16,  followed by HPV-31 (14.6ｵ),  HPV 
-18 (12.5ｵ),  and HPV-58 (12.5ｵ).
　 In the present study,  59.3ｵ of women with cervi-
cal neoplasia treated at Sanpya General Hospital 
located in the emerging urban area of Yangon city,  
Myanmar,  were positive for HR-HPV which was 
detected in 44.4ｵ of CIN1 cases,  63.2ｵ of CIN2,  
70.6ｵ of CIN3,  and 74.1ｵ of SCC (Table 1).  
Analysis of the studies done in Myanmar demonstrated 
that the highest prevalence of HR-HPV was in SCC 
cases.  This study was consistent with the other stud-
ies mentioned above.  The association between cervical 
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A HPVﾝ16 B HPVﾝ18
C HPVﾝ31 D HPVﾝ58
Fig. 2　 Proportion of human papillomavirus genotypes A,  HPV-16 B,  HPV-18 C,  HPV-31 D,  HPV-58 in cervical neoplasia by age 
group.
neoplasia and HPV positivity was highly signiﬁcant 
(p＝0.008).  Thus if a patient is found positive for an 
HR-HPV genotype,  the possibility of cervical neopla-
sia can be predicted.  HPV testing improves the 
accuracy of colposcopy in the detection of CIN in 
women with ASCUS and LSIL cytological changes 
[24].
　 In the present study,  65.6ｵ of HR-HPV cases 
were HPV-16,  followed by HPV-31 (21.9ｵ),  HPV 
-18 (7.8ｵ) and HPV-58 (4.7ｵ).  Among the cervical 
cancer cases,  HPV-16 and -18 were most commonly 
detected.  Analysis of both studies conducted in 
Myanmar showed that HPV-16 was the most common 
genotype (60.4ｵ vs. 65.6ｵ).  HPV-31 was the sec-
ond-most prevalent genotype in both studies (14.6ｵ 
vs. 21.9ｵ).  HPV-18 was the third-most prevalent 
genotype (12.5ｵ vs. 7.8ｵ),  and HPV-58 was found 
with low prevalence (12.5ｵ vs. 4.7ｵ) in the 2 studies.  
An interesting ﬁnding in the present study was that 
HPV-16 and -31 were detected in all CIN1,  CIN2,  
CIN3,  and SCC cases.
　 There were no signiﬁcant diﬀerences among HPV 
genotypes in this newly developing area,  i.e,  in the 
periphery of Yangon,  Myanmar,  compared with the 
previous study [23].  The most prevalent genotype was 
HPV-16 followed by HPV-31,  HPV-18 and HPV-58.  
Most of the studies have shown that HPV-16 was the 
most prevalent genotype associated with cervical 
neoplaisa [20,  21,  22].  One limitation of por study 
was the use of a methodology involving consensus 
primers that could detect seven genotypes of HPV-
DNA (HPV-16,  -18,  -31,  -33,  -35,  -52b,  and 
-58).  Thus restriction enzymes could diﬀerentiate 
those seven genotypes in this study.  More advanced 
molecular technology such as molecular array and 
sequencing methods should be performed.
　 Recently,  multiple types of HPV infections have 
been analyzed because,  with the development of anti-
HPV vaccines that do not cover all genotypes,  the 
distribution of infection due to types not covered by 
vaccines could be aﬀected.  The elimination of one 
HPV type could aﬀect the natural history of the 
remaining genotypes.  Therefore,  it is becoming 
imperative to obtain solid knowledge of genotype HPV 
distribution.  Multiple types of HPV have been 
observed in up to 50ｵ of NC and LSIL cases in 
Northwest Spain [25].  It is still not clear whether 
co-infection with several types increases the risk of 
progression.  It seems that,  as lesions progress from 
low to high grade,  HR oncogenic types may persist,  
whereas less oncogenic types are eliminated [26].  A 
limitation of our study was the use of a methodology 
that could detect only seven HPV genotypes.  If more 
advanced molecular methods that can detect multiple 
types were performed,  multiple HPV infections could 
be analyzed.
　 According to our data,  the prevalence rates of 
HR-HPV in women in diﬀerent age groups with cervi-
cal neoplasia (30-39 yrs,  40-49 yrs,  and 50-59 yrs) 
did not diﬀer signiﬁcantly (X2＝1.16,  p＝0.28).  This 
ﬁnding was consistent with Jariene K et al.  [22].  In 
the present study,  the youngest woman suﬀering from 
ISCC who was HR-HPV positive was 22 years old,  
and the oldest was 76 years old.  90.6ｵ of HPV-16 
positive cases and 78.6ｵ of HPV-31 positive cases 
were found in women aged between 30 to 59 years.  
HPV-18 and HPV-58 were more commonly found in 
older age groups,  with 40ｵ of HPV-18 cases and 
66.7ｵ of HPV-58 cases found in women 60 years old 
and older.
　 The ﬁrst peak of HR-HPV prevalence was 
observed in women in their early 20s up to 25 years 
[2],  but these infections were mostly transient [27].  
Severe cervical intraepithelial changes are also observed 
in teenagers and women up to 25 years of age just 
after the acquisition of HR-HPV infection [28].  
According to the data reported,  the peak incidence of 
HPV infection occurs within 5 to 10 years after the 
beginning of sexual activity.  The prevalence of HPV 
decreases with age,  but its persistence increases 
[29].  According to our data,  there was no signiﬁcant 
diﬀerence in the prevalence of HPV in women of dif-
ferent age groups.  This may be because the present 
study was focused on the prevalence of HR-HPV in 
women with CIN/SCC,  and not in the general popula-
tion.
　 The methods commonly used to treat precancerous 
cervical lesions with or without HPV infection include 
cryosurgery (freezing that destroys tissue),  the loop 
electrosurgical excision procedure (LEEP,  which is 
the removal of cervical tissue using a hot wire loop),  
surgical conization (surgery with a scalpel,  a laser,  or 
both to remove a cone-shaped piece of tissue from the 
cervix and cervical canal),  and laser vaporization 
conization (the use of a laser to destroy cervical tis-
sue).
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　 If a woman with NC is infected with HPV that can 
lead to cancer,  frequent Pap tests are needed to 
watch for signs of abnormal cell changes in the genital 
area.  Abnormal cell changes in the cervix are a warn-
ing sign of possible cervical cancer.  In cases of LSIL 
and HSIL determined by cytology,  colposcopy-directed 
biopsy should be performed to obtain an accurate 
diagnosis.  Regarding the management of HPV-positive 
and HPV-negative patients with cervical cancer,  
HPV-infected individuals who develop cervical cancer 
generally receive the same treatment as patients 
whose tumors do not harbor HPV infections,  accord-
ing to the type and stage of their tumors.  However,  
people who are diagnosed with HPV-positive oropha-
ryngeal cancer may be treated diﬀerently than people 
with oropharyngeal cancers that are HPV-negative.  
Recent research has shown that patients with HPV-
positive oropharyngeal tumors have a better prognosis 
and may do just as well on less intense treatment.  An 
ongoing clinical trial is investigating this question.
　 Prophylactic HPV vaccines have been developed 
against HPV-16 and HPV-18 based on virus-like 
particles (VLPs) and which induce high titer of neu-
tralizing antibodies; they could potentially prevent 
70ｵ of cervical cancers worldwide.  These vaccines 
are more than 90ｵ eﬀective at preventing type 16/18 
associated CIN,  although their overall eﬃcacy against 
all types (CIN2/3) in all vaccine recipients irrespec-
tive of current infection is considerably less [30].  
The rationale for prophylactic HPV vaccination is 
based on the necessity of HPV infection in cervical 
carcinogenesis,  so that by preventing this primary 
event,  secondary changes which result in cytological 
abnormalities will also be prevented.  The vaccine is 
intended to prevent  pathological change in the cervix 
because the infection itself is asymptomatic and does 
not cause acute damage.  This concept of preventing a 
viral infection in order to prevent a subsequent cancer,  
which might otherwise not occur for 25 years,  is novel.
　 In Myanmar,  only an opportunistic cervical screen-
ing program is present.  There is no HPV vaccination 
program.  Also,  HPV-DNA testing could not be per-
formed as a method of early detection of cervical 
cancer in clinical practice.  Our study identiﬁed the 
prevalent HPV genotypes associated with diﬀerent 
cervical neoplasia types so we could assess the useful-
ness of HPV vaccination in Myanmar.  Before the 
start of a vaccination program,  we should collect more 
evidence-based data about the prevalent HPV geno-
types associated with cervical neoplasia in Myanmar.
　 The authors suggest that a strategy of primary 
prevention is needed to reduce the morbidity associ-
ated with the management of abnormal cytology.  Such 
a strategy would also oﬀer a potential means of pre-
vention in countries without any cervical screening,  
including many underdeveloped countries with high 
rates of cervical cancer.  However,  screening is 
needed because of the limitations of the current HPV 
vaccines,  both in their lack of a therapeutic eﬀect 
(i.e.,  their inability to protect women with an ongoing 
neoplastic process) and in the limited number of HPV 
types they can prevent (thus allowing some 25-30ｵ of 
cervical cancer cases related to HPV types other than 
-16 and -18 to develop).  A combination of both 
screening and vaccination is reasonable in a setting 
where screening is already developed and reasonably 
eﬃcient.
　 The development of polyvalent vaccines (including 
some 5-8 HPV types) will extend protection to be 
eﬀective against more than 90ｵ of the oncogenic 
HPV types,  and when such vaccines are achieved,  
vaccination alone would be suﬃcient.  At present,  no 
vaccination can provide total protection.  Patients with 
cervical neoplasia infected with HPV prior to vaccina-
tion will not be protected and will still be at risk of 
infection with other non-vaccine HPV types.
　 In conclusion,  this study detected the oncogenic 
HPV genotypes-16,  -31,  -18 and -58 in the majority 
of CIN and cervical cancer cases in Myanmar.  If the 
oncogenic HPV genotypes are positive,  the possibility 
of cervical neoplasia can be predicted.  Knowledge of 
the distribution of HPV genotypes can make it possi-
ble to predict the eﬀectiveness of the currently used 
HPV vaccine.  As HPV genotypes -16 and -18 are the 
vaccine-preventable genotypes that are associated with 
cervical cancer,  primary prevention of cervical cancer 
by HPV vaccination in the adolescent age group should 
be promoted in Myanmar,  as it would reduce the 
incidence of cervical cancer and the associated mortal-
ity and morbidity.
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